Debt, Derivatives and Royalty certificates liabilities - Short-term derivatives (Details)
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
Dec. 02, 2025
shares
|
Sep. 01, 2025
shares
|
May 07, 2025
EUR (€)
€ / shares
shares
|
Apr. 28, 2025
shares
|
Dec. 19, 2024
EUR (€)
€ / shares
shares
|
Dec. 11, 2024
EUR (€)
€ / shares
D
shares
|
Oct. 17, 2024
EUR (€)
€ / shares
shares
|
May 31, 2025
EUR (€)
€ / shares
shares
|
Dec. 31, 2025
EUR (€)
€ / shares
shares
|
Dec. 31, 2024
EUR (€)
€ / shares
shares
|
Dec. 31, 2023
EUR (€)
|
Oct. 14, 2024
EUR (€)
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities | € |
|
|
|
|
|
|
|
|
|
€ 73,400,000
|
|
|
| Par value per share | € / shares |
|
|
|
|
|
|
|
|
€ 0.01
|
|
|
|
| Proceeds from issuance of shares | € |
|
|
|
|
|
|
|
|
€ 206,441,000
|
57,338,000
|
€ 30,589,000
|
|
| Issue of prefunded warrants | € |
|
|
|
|
|
|
|
|
138,130,000
|
58,227,000
|
|
|
| T2 New Shares and T2 BSAs call options |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities | € |
|
|
€ 158,100,000
|
|
|
|
|
|
|
73,400,000
|
|
|
| Losses on fair value variation | € |
|
|
|
|
|
|
|
|
(84,700,000)
|
|
|
|
| Financial liabilities carried at fair value through profit or loss |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities | € |
|
|
|
|
|
|
|
|
|
73,400,000
|
|
€ 89,400,000
|
| 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds | € |
|
|
|
|
|
|
|
€ 115,600,000
|
|
|
|
|
| Tranche I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued during period upon exercise of warrants | shares |
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
| Tranche I, phase I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds | € |
|
|
|
|
|
|
|
|
|
94,100,000
|
|
|
| Net proceeds | € |
|
|
|
|
|
|
|
|
|
86,600,000
|
|
|
| Tranche I, phase II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds | € |
|
|
|
|
€ 21,400,000
|
|
|
|
|
21,400,000
|
|
|
| Net proceeds | € |
|
|
|
|
€ 20,100,000
|
|
|
|
|
€ 20,100,000
|
|
|
| Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds | € |
|
|
115,600,000
|
|
|
|
|
115,600,000
|
|
|
|
|
| Net proceeds | € |
|
|
108,500,000
|
|
|
|
|
€ 108,500,000
|
|
|
|
|
| Fair Value (in millions of euros) | € |
|
|
273,700,000
|
|
|
|
|
|
|
|
|
|
| Tranche II, 2024 Financing arrangement in three tranches | T2 New Shares and T2 BSAs call options |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities | € |
|
|
€ 158,100,000
|
|
|
|
|
|
|
|
|
|
| Tranche III, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum proceeds from exercise of warrants | € |
|
|
|
|
|
|
|
|
€ 116,000,000
|
|
|
|
| T2 BSA Prefunded Warrants | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
|
43,437,036
|
|
|
|
|
43,437,036
|
|
|
|
|
| Number of shares callable by warrants | shares |
|
|
|
|
|
|
|
43,437,036
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
|
| Subscription price per warrant | € / shares |
|
|
€ 1.34
|
|
|
|
|
1.34
|
|
|
|
|
| Par value per share | € / shares |
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
| Aggregate gross proceed | € |
|
|
|
|
|
€ 58,639,998.6
|
|
|
|
|
|
|
| Exercise price per warrant | € / shares |
|
|
|
|
|
|
|
€ 1.35
|
|
|
|
|
| Adjustment to warrant subscription price | € / shares |
|
|
|
|
|
€ 0.01
|
|
|
|
|
|
|
| Number of shares per warrant | shares |
|
|
1
|
|
|
1
|
|
1
|
|
1
|
|
|
| Number of instruments | shares |
|
|
43,400,000
|
|
|
43,400,000
|
|
|
|
43,400,000
|
|
|
| Stock price | € / shares |
|
|
€ 3.19
|
|
|
|
|
|
|
|
|
|
| Stock price | € / shares |
|
|
|
|
|
€ 2.37
|
|
|
|
€ 2.18
|
|
|
| Maturity term of warrants |
|
|
|
|
|
3 months 15 days
|
|
|
|
3 months
|
|
|
| Expected volatility |
|
|
|
|
|
59.30%
|
|
|
|
58.30%
|
|
|
| Fair value of potential warrants | € |
|
|
€ 138,100,000
|
|
|
€ 45,400,000
|
|
|
|
€ 37,300,000
|
|
|
| Unit Fair value (€) | € / shares |
|
|
3.18
|
|
|
1.05
|
|
|
|
0.86
|
|
|
| Issue of prefunded warrants | € |
|
|
€ 138,100,000
|
|
|
|
|
|
|
|
|
|
| T2 BSA Prefunded Warrants | Tranche II, 2024 Financing arrangement in three tranches | T2 BSA Call options |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities | € |
|
|
€ 79,900,000
|
|
|
|
|
|
|
|
|
|
| T1 BSA Warrants | Tranche I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants exercised | shares |
|
|
|
|
|
|
|
|
9,372,755
|
|
|
|
| Shares issued during period upon exercise of warrants | shares |
|
|
|
|
|
|
|
|
9,372,755
|
|
|
|
| T1 BSA Warrants | Tranche I, phase I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
|
|
|
|
|
35,399,481
|
|
|
35,399,481
|
|
|
| Number of shares callable by warrants | shares |
|
|
|
|
|
|
35,399,481
|
|
|
35,399,481
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
|
€ 0.01
|
|
|
€ 0.01
|
|
|
| Subscription price per warrant | € / shares |
|
|
|
|
|
|
€ 1.34
|
|
|
1.34
|
|
|
| Gross proceeds | € |
|
|
|
|
|
|
€ 94,100,000
|
|
|
|
|
|
| Net proceeds | € |
|
|
|
|
|
|
€ 86,600,000
|
|
|
|
|
|
| Shares issued during period upon exercise of warrants | shares |
1,251,724
|
6,800,000
|
|
|
|
|
|
|
|
|
|
|
| Exercise price per warrant | € / shares |
|
|
|
|
|
|
€ 0.01
|
|
|
€ 0.01
|
|
|
| T1 bis BSA Warrants | Tranche I, phase II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issued | shares |
|
|
|
|
8,053,847
|
|
|
|
|
8,053,847
|
|
|
| Number of shares callable by warrants | shares |
|
|
|
|
8,053,847
|
|
|
|
|
8,053,847
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
€ 0.01
|
|
|
|
|
€ 0.01
|
|
|
| Subscription price per warrant | € / shares |
|
|
|
|
1.34
|
|
|
|
|
|
|
|
| Exercise price per warrant | € / shares |
|
|
|
|
€ 0.01
|
|
|
|
|
0.01
|
|
|
| Warrants, Subscription Price | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.34
|
|
|
| T1 New Share | Tranche I, phase I, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
|
|
|
|
|
34,600,507
|
|
|
34,600,507
|
|
|
| Price per share | € / shares |
|
|
|
|
|
|
€ 1.35
|
|
|
€ 1.35
|
|
|
| T2 New Share | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
|
42,488,883
|
|
|
|
42,488,883
|
42,488,883
|
|
|
|
|
| Par value per share | € / shares |
|
|
€ 0.01
|
|
|
|
|
|
|
|
|
|
| Number of instruments | shares |
|
|
42,500,000
|
|
|
42,500,000
|
|
|
|
42,500,000
|
|
|
| Number of shares per instruments | shares |
|
|
1
|
|
|
1
|
|
|
|
1
|
|
|
| Stock price | € / shares |
|
|
€ 3.19
|
|
|
€ 2.37
|
|
|
|
€ 2.18
|
|
|
| Maturity |
|
|
|
|
|
3 months 15 days
|
|
|
|
3 months
|
|
|
| Expected volatility |
|
|
|
|
|
59.30%
|
|
|
|
58.30%
|
|
|
| Fair value of potential shares | € |
|
|
€ 135,500,000
|
|
|
€ 44,000,000
|
|
|
|
€ 36,100,000
|
|
|
| Price per share | € / shares |
|
|
€ 1.35
|
|
|
|
€ 1.35
|
|
|
|
|
|
| Proceeds from issuance of shares | € |
|
|
€ 57,400,000
|
|
|
|
€ 57,400,000
|
|
|
|
|
|
| Unit fair value | € / shares |
|
|
3.19
|
|
|
1.04
|
|
|
|
0.85
|
|
|
| T2 New Share | Tranche II, 2024 Financing arrangement in three tranches | T2 New Shares Call options |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities | € |
|
|
€ 78,200,000
|
|
|
|
|
|
|
|
|
|
| T2 New Share | If five day volume weighted average price more than €1.35 | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Call option strike price | € / shares |
|
|
|
|
|
€ 1.35
|
|
|
€ 1.35
|
|
|
|
| Call option, conversion ratio |
|
|
|
|
|
|
|
|
1
|
|
|
|
| T2 New Share | ABSA warrants | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate gross proceed | € |
|
|
|
|
|
€ 57,359,992
|
|
|
|
|
|
|
| Number of trading days of volume weighted average price | D |
|
|
|
|
|
5
|
|
|
|
|
|
|
| T1 bis Shares | Tranche I, phase II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued during the period | shares |
|
|
|
|
7,872,064
|
|
|
|
|
7,872,064
|
|
|
| Price per share | € / shares |
|
|
|
|
€ 1.35
|
|
|
|
|
€ 1.35
|
|
|
| Maximum | T2 BSA Prefunded Warrants | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
€ 1.35
|
|
|
|
|
|
|
| Exercise price per warrant | € / shares |
|
|
|
|
|
1.35
|
|
|
|
|
|
|
| Maximum | T3 BSA warrants | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Additional proceeds receivable upon exercise of warrants | € |
|
|
€ 116,000,000
|
|
|
|
|
|
€ 116,000,000
|
|
|
|
| Maximum | T2 New Share | ABSA warrants | Tranche II, 2024 Financing arrangement in three tranches |
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of detailed information about borrowings [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant | € / shares |
|
|
|
|
|
1.35
|
|
|
|
|
|
|
| Exercise price per warrant | € / shares |
|
|
|
|
|
€ 1.35
|
|
|
|
|
|
|